Context Therapeutics (CNTX) Research & Development (2020 - 2026)

Context Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $7.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $7.0 million, up 102.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.4 million (up 46.37% YoY), and the FY2025 annual result was $31.9 million, up 40.33% from the prior year.
• Research & Development came in at $7.0 million for Q1 2026 at Context Therapeutics, down from $11.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.8 million in Q3 2024 to a low of $1.4 million in Q1 2022.
• The 5-year median for Research & Development is $3.5 million (2025), against an average of $5.1 million.
• Across the five-year window, Research & Development sank 59.99% in 2024 and surged 465.56% in 2025, its largest moves.
• Context Therapeutics' Research & Development stood at $2.1 million in 2022, then surged by 147.19% to $5.3 million in 2023, then sank by 52.5% to $2.5 million in 2024, then jumped by 370.17% to $11.8 million in 2025, then slumped by 40.75% to $7.0 million in 2026.
• The last three Research & Development figures came in at $7.0 million (Q1 2026), $11.8 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.